U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H13I3N2O3
Molecular Weight 613.9571
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOCETAMIC ACID

SMILES

CC(CN(C(=O)C)c1c(cc(c(c1I)N)I)I)C(=O)O

InChI

InChIKey=GSVQIUGOUKJHRC-UHFFFAOYSA-N
InChI=1S/C12H13I3N2O3/c1-5(12(19)20)4-17(6(2)18)11-8(14)3-7(13)10(16)9(11)15/h3,5H,4,16H2,1-2H3,(H,19,20)

HIDE SMILES / InChI
Iocetamic acid is a medical diagnostic aid. It is a contrast agent used to enhance structures or fluids during X-ray imaging.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
CHOLEBRINE

Approved Use

Unknown
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20 h
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IOCETAMIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IOCETAMIC ACID plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Other AEs: Ankle swelling, Feeling of warmth...
Other AEs:
Ankle swelling (6 patients)
Feeling of warmth (10 patients)
Chest pain (4 patients)
Headache (14 patients)
Paraesthesia (6 patients)
Dizziness (10 patients)
Sources:
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Other AEs: Vomiting, Nausea...
Other AEs:
Vomiting (1 patient)
Nausea (14 patients)
Watery diarrhoea (1 patient)
Loose bowels (3 patients)
Abdominal pain (12 patients)
Eructation (19 patients)
Flatus (15 patients)
Nocturia (21 patient)
Discolouration urine (5 patients)
Itchy skin (3 patients)
Blister (2 patients)
Skin rash (1 patient)
Bruising (2 patients)
Wheezing (9 patients)
Breathlessness (9 patients)
Nocturnal dyspnoea (3 patients)
Sources:
4.5 g single, oral
Highest studied dose
Dose: 4.5 g
Route: oral
Route: single
Dose: 4.5 g
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Disc. AE: Skin infection...
AEs leading to
discontinuation/dose reduction:
Skin infection (severe, 1 patient)
Sources:
3 g single, oral
Dose: 3 g
Route: oral
Route: single
Dose: 3 g
Sources:
unhealthy
n = 2
Health Status: unhealthy
Population Size: 2
Sources:
Disc. AE: Skin infection...
AEs leading to
discontinuation/dose reduction:
Skin infection (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 10 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Feeling of warmth 10 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Headache 14 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Chest pain 4 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Ankle swelling 6 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Paraesthesia 6 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 48
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 48
Sources:
Skin rash 1 patient
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Vomiting 1 patient
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Watery diarrhoea 1 patient
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Abdominal pain 12 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Nausea 14 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Flatus 15 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Eructation 19 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Blister 2 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Bruising 2 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Nocturia 21 patient
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Itchy skin 3 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Loose bowels 3 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Nocturnal dyspnoea 3 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Discolouration urine 5 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Breathlessness 9 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Wheezing 9 patients
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, adult
n = 49
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 49
Sources:
Skin infection severe, 1 patient
Disc. AE
4.5 g single, oral
Highest studied dose
Dose: 4.5 g
Route: oral
Route: single
Dose: 4.5 g
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Skin infection 2 patients
Disc. AE
3 g single, oral
Dose: 3 g
Route: oral
Route: single
Dose: 3 g
Sources:
unhealthy
n = 2
Health Status: unhealthy
Population Size: 2
Sources:
Patents

Patents

Sample Use Guides

Administer 750 mg on the examination day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
IOCETAMIC ACID
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
MP-620
Code English
N-ACETYL-N-(3-AMINO-2,4,6-TRIIODOPHENYL)-2-METHYL-.BETA.-ALANINE
Systematic Name English
IOCETAMIC ACID [WHO-DD]
Common Name English
IOCETAMIC ACID [HSDB]
Common Name English
CHOLEBRINE
Brand Name English
IOCETAMIC ACID [VANDF]
Common Name English
IOCETAMIC ACID [ORANGE BOOK]
Common Name English
PROPANOIC ACID, 3-(ACETYL(3-AMINO-2,4,6-TRIIODOPHENYL)AMINO)-2-METHYL-
Common Name English
IOCETAMIC ACID [MART.]
Common Name English
IOCETAMIC ACID [INN]
Common Name English
IOCETAMIC ACID [MI]
Common Name English
IOCETAMIC ACID [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28500
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
WHO-VATC QV08AC07
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
WHO-ATC V08AC07
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
Code System Code Type Description
MERCK INDEX
M6324
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
240-173-1
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
FDA UNII
FA675Q0E3E
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
DRUG BANK
DB09403
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
CAS
16034-77-8
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
DRUG CENTRAL
1451
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
HSDB
3344
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
INN
2347
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
PUBCHEM
27648
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200770
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
NCI_THESAURUS
C65927
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
EVMPD
SUB08209MIG
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY
RXCUI
183830
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY RxNorm
EPA CompTox
16034-77-8
Created by admin on Sat Jun 26 12:28:41 UTC 2021 , Edited by admin on Sat Jun 26 12:28:41 UTC 2021
PRIMARY